Beyond TAXUS^TM: Next-Generation Drug-Eluting Stent Systems

The TAXUS system represents the first of many drug-eluting stents in our pipeline, and we are already well on our way to delivering what’s next. The Liberté bare-metal stent, launched in international markets in the first quarter of 2004, will serve as the platform for Boston Scientific’s next-generation drug-eluting stent system. The Liberté stent is engineered to provide enhanced flexibility, vessel conformability and strength. We hope to launch the TAXUS Liberté drug-eluting stent system in international markets during the second half of 2004.